Skip to main content
SpringerLink
Log in

Infantile and Congenital Hemangiomas: Natural History, Complications, and When and How to Treat

  • Chapter
  • First Online:
Vascular Anomalies

Abstract

Infantile and congenital hemangiomas are benign vascular tumors of infancy. Typical infantile hemangiomas are common, and though usually innocent, they are extremely heterogeneous and may yield a range of complications depending on their morphology, size, or location. Interventions for infantile hemangiomas include topical, intralesional, and systemic therapies, including oral propranolol, which has revolutionized our management of IH over the past recent years.

Congenital hemangiomas are uncommon and are distinct from infantile hemangiomas and follow their own unique life cycle and growth characteristics. Congenital hemangiomas (CH) also have varied clinical presentations and complications. Distinguishing CH from other vascular tumors and malformations is essential to anticipate complications and guide treatment.

In the following chapter, authors aim to provide a framework for the hematologist/oncologist regarding the management of infantile and congenital hemangiomas. We will provide a thorough review of each lesion including their specific growth characteristics and clinical course as well as complications to worry about. Treatments for both infantile and congenital hemangiomas will be reviewed in detail and categorized according to their appropriate use in different clinical settings.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kanada KN, Merin MR, Munden A, Friedlander SF. A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr. 2012;161(2):240–5.

    PubMed  Google Scholar 

  2. Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents’ photographs tell us. Pediatrics. 2012;130(2):e314–20.

    PubMed  Google Scholar 

  3. Suh KY, Frieden IJ. Infantile hemangiomas with minimal or arrested growth: a retrospective case series. Arch Dermatol. 2010;146(9):971–6.

    PubMed  Google Scholar 

  4. Haggstrom AN, Garzon MC, Baselga E, Chamlin SL, Frieden IJ, Holland K, et al. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics. 2010;126(2):e418–26.

    PubMed  Google Scholar 

  5. Metry D, Heyer G, Hess C, Garzon M, Haggstrom A, Frommelt P, et al. Consensus statement on diagnostic criteria for PHACE syndrome. Pediatrics. 2009;124(5):1447–56.

    PubMed  Google Scholar 

  6. Bayer ML, Frommelt PC, Blei F, Breur JM, Cordisco MR, Frieden IJ, et al. Congenital cardiac, aortic arch, and vascular bed anomalies in PHACE syndrome (from the international PHACE syndrome registry). Am J Cardiol. 2013;112(12):1948–52.

    PubMed  PubMed Central  Google Scholar 

  7. Iacobas I, Burrows PE, Frieden IJ, Liang MG, Mulliken JB, Mancini AJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr. 2010;157(5):795–801 e1-7.

    PubMed  Google Scholar 

  8. Frade F, Kadlub N, Soupre V, Cassier S, Audry G, Vazquez MP, et al. PELVIS or LUMBAR syndrome: the same entity. Two case reports. Arch Pediatr. 2012;19(1):55–8.

    CAS  PubMed  Google Scholar 

  9. Yadav DK, Panda SS, Teckchandani N, Bagga D. SACRAL syndrome. BMJ Case Rep. 2013;2013.

    Google Scholar 

  10. Chamlin SL, Haggstrom AN, Drolet BA, Baselga E, Frieden IJ, Garzon MC, et al. Multicenter prospective study of ulcerated hemangiomas. J Pediatr. 2007;151(6):684–9, 9 e1.

    PubMed  Google Scholar 

  11. Maguiness SM, Hoffman WY, McCalmont TH, Frieden IJ. Early white discoloration of infantile hemangioma: a sign of impending ulceration. Arch Dermatol. 2010;146(11):1235–9.

    PubMed  Google Scholar 

  12. Di Maio L, Baldi A, Dimaio V, Barzi A. Use of flashlamp-pumped pulsed dye laser in the treatment of superficial vascular malformations and ulcerated hemangiomas. In Vivo. 2011;25(1):117–23.

    PubMed  Google Scholar 

  13. Oranje AP, Janmohamed SR, Madern GC, de Laat PC. Treatment of small superficial haemangioma with timolol 0.5% ophthalmic solution: a series of 20 cases. Dermatology. 2011;223(4):330–4.

    CAS  PubMed  Google Scholar 

  14. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649–51.

    CAS  PubMed  Google Scholar 

  15. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128(2):e259–66.

    PubMed  Google Scholar 

  16. Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735–46.

    CAS  PubMed  Google Scholar 

  17. Gonski K, Wargon O. Retrospective follow up of gross motor development in children using propranolol for treatment of infantile haemangioma at Sydney Children’s Hospital. Australas J Dermatol. 2014;55(3):209–11.

    PubMed  Google Scholar 

  18. Bauman NM, McCarter RJ, Guzzetta PC, Shin JJ, Oh AK, Preciado DA, et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2014;140(4):323–30.

    PubMed  Google Scholar 

  19. Ji Y, Chen S, Xu C, Li L, Xiang B. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol. 2015;172(1):24–32.

    CAS  PubMed  Google Scholar 

  20. Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128–40.

    PubMed  PubMed Central  Google Scholar 

  21. Hoeger PH, Harper JI, Baselga E, Bonnet D, Boon LM, Atti MC, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174(7):855–65.

    CAS  PubMed  Google Scholar 

  22. Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics. 2013;131(6):e1739–47.

    PubMed  Google Scholar 

  23. Couto JA, Greene AK. Management of problematic infantile hemangioma using intralesional triamcinolone: efficacy and safety in 100 infants. J Plast Reconstr Aesthet Surg. 2014;67(11):1469–74.

    PubMed  Google Scholar 

  24. Batta K, Goodyear HM, Moss C, Williams HC, Hiller L, Waters R. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Lancet. 2002;360(9332):521–7.

    PubMed  Google Scholar 

  25. Mulliken JB, Enjolras O. Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol. 2004;50(6):875–82.

    PubMed  Google Scholar 

  26. Nasseri E, Piram M, McCuaig CC, Kokta V, Dubois J, Powell J. Partially involuting congenital hemangiomas: a report of 8 cases and review of the literature. J Am Acad Dermatol. 2014;70(1):75–9.

    PubMed  Google Scholar 

  27. Maguiness S, Uihlein LC, Liang MG, Kozakewich H, Mulliken JB. Rapidly involuting congenital hemangioma with fetal involution. Pediatr Dermatol. 2015;32(3):321–6.

    PubMed  Google Scholar 

  28. Gorincour G, Kokta V, Rypens F, Garel L, Powell J, Dubois J. Imaging characteristics of two subtypes of congenital hemangiomas: rapidly involuting congenital hemangiomas and non-involuting congenital hemangiomas. Pediatr Radiol. 2005;35(12):1178–85.

    PubMed  Google Scholar 

  29. Lee PW, Frieden IJ, Streicher JL, McCalmont T, Haggstrom AN. Characteristics of noninvoluting congenital hemangioma: a retrospective review. J Am Acad Dermatol. 2014;70(5):899–903.

    PubMed  Google Scholar 

  30. Liang MG, Frieden IJ. Infantile and congenital hemangiomas. Semin Pediatr Surg. 2014;23(4):162–7.

    PubMed  Google Scholar 

  31. Boon LM, Enjolras O, Mulliken JB. Congenital hemangioma: evidence of accelerated involution. J Pediatr. 1996;128(3):329–35.

    CAS  PubMed  Google Scholar 

  32. Cole P, Kaufman Y, Metry D, Hollier L. Non-involuting congenital haemangioma associated with high-output cardiomyopathy. J Plast Reconstr Aesthet Surg. 2009;62(10):e379–82.

    PubMed  Google Scholar 

  33. Weitz NA, Lauren CT, Starc TJ, Kandel JJ, Bateman DA, Morel KD, et al. Congenital cutaneous hemangioma causing cardiac failure: a case report and review of the literature. Pediatr Dermatol. 2013;30(6):e180–90.

    PubMed  Google Scholar 

  34. Daniel SJ, Cassady G. Non-immunologic hydrops fetalis associated with a large hemangioendothelioma. Pediatrics. 1968;42(5):828–33.

    CAS  PubMed  Google Scholar 

  35. McGahan JP, Schneider JM. Fetal neck hemangioendothelioma with secondary hydrops fetalis: sonographic diagnosis. J Clin Ultrasound. 1986;14(5):384–8.

    CAS  PubMed  Google Scholar 

  36. Dickie B, Dasgupta R, Nair R, Alonso MH, Ryckman FC, Tiao GM, et al. Spectrum of hepatic hemangiomas: management and outcome. J Pediatr Surg. 2009;44(1):125–33.

    PubMed  Google Scholar 

  37. Christison-Lagay ER, Burrows PE, Alomari A, Dubois J, Kozakewich HP, Lane TS, et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg. 2007;42(1):62–7; discussion 7-8.

    PubMed  Google Scholar 

  38. Hsi Dickie B, Fishman SJ, Azizkhan RG. Hepatic vascular tumors. Semin Pediatr Surg. 2014;23(4):168–72.

    PubMed  Google Scholar 

  39. Alomari AI. Hepatic arteriovenous malformation or rapidly involuting congenital hemangioma? Tex Heart Inst J. 2015;42(4):408.

    PubMed  PubMed Central  Google Scholar 

  40. Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med. 2000;343(3):185–9.

    CAS  PubMed  Google Scholar 

  41. Klein M, Chang AK, Vasudevan SA, Blatt J, Iacobas I, Lee S. Clinically significant ascites as an indication for resection of rapidly involuting congenital hepatic hemangiomas. Pediatr Blood Cancer. 2018;65(8):e27222.

    PubMed  PubMed Central  Google Scholar 

  42. Rialon KL, Murillo R, Fevurly RD, Kulungowski AM, Christison-Lagay ER, Zurakowski D, et al. Risk factors for mortality in patients with multifocal and diffuse hepatic hemangiomas. J Pediatr Surg. 2015;50(5):837–41.

    PubMed  Google Scholar 

  43. Rialon KL, Murillo R, Fevurly RD, Kulungowski AM, Zurakowski D, Liang M, et al. Impact of screening for hepatic hemangiomas in patients with multiple cutaneous infantile hemangiomas. Pediatr Dermatol. 2015;32(6):808–12.

    PubMed  Google Scholar 

  44. Mhanna A, Franklin WH, Mancini AJ. Hepatic infantile hemangiomas treated with oral propranolol--a case series. Pediatr Dermatol. 2011;28(1):39–45.

    PubMed  Google Scholar 

  45. Marsciani A, Pericoli R, Alaggio R, Brisigotti M, Vergine G. Massive response of severe infantile hepatic hemangioma to propranolol. Pediatr Blood Cancer. 2010;54(1):176.

    PubMed  Google Scholar 

  46. Ayturk UM, Couto JA, Hann S, Mulliken JB, Williams KL, Huang AY, Fishman SJ, Boyd TK, Kozakewich HP, Bischoff J, Greene AK. Somatic activating mutations in GNAQ and GNA11 are associated with congenital hemangioma. Am J Human Genet. 2016;98(4):789–95.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Columbia University Medical Center, New York, NY, USA

    Margaret T. Lee

  2. Dermatology, University of Minnesota, Minneapolis, MN, USA

    Sheilagh Maguiness

Authors
  1. Margaret T. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheilagh Maguiness
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret T. Lee .

Editor information

Editors and Affiliations

  1. Dana-Farber Cancer Institute, Boston Children’s Hospital, Boston, MA, USA

    Cameron C. Trenor III

  2. Dana-Farber Cancer Institute, Boston Children’s Hospital, Boston, MA, USA

    Denise M. Adams

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lee, M.T., Maguiness, S. (2020). Infantile and Congenital Hemangiomas: Natural History, Complications, and When and How to Treat. In: Trenor III, C., Adams, D. (eds) Vascular Anomalies. Springer, Cham. https://doi.org/10.1007/978-3-030-25624-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25624-1_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25622-7

  • Online ISBN: 978-3-030-25624-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation